Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Conjuchem DAC:GLP-1 Phase II data

Conjuchem (TSE:CJC) said in an international Phase II trial in 206 Type II diabetes patients, DAC:GLP-1

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE